Our Pipeline

Based on its platform technology T3 Pharma has built a pipeline which is constantly expanded further - with the aim to harness the full potential of tumour specific bacteria delivering proteins. T3 Pharma's porgrams in clinical development can be found here.

T3P-Y058-739 is T3 Pharma's lead asset with a mode of action on inducing a highly specific immune response selectively within solid tumours. Its way of functioning is shown in the animation below: